CSIMarket Company Name, Ticker, Competitors, else..
 
Bright Minds Biosciences Inc   (NASDAQ: DRUG)
Other Ticker:  
 
 
Price: $37.2950 $1.73 4.850%
Day's High: $37.6 Week Perf: 6.1 %
Day's Low: $ 35.37 30 Day Perf: 10.77 %
Volume (M): 7 52 Wk High: $ 79.02
Volume (M$): $ 248 52 Wk Avg: $17.80
Open: $35.37 52 Wk Low: $0.93



 Market Capitalization (Millions $) 139
 Shares Outstanding (Millions) 4
 Employees 57
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Bright Minds Biosciences Inc
Bright Minds Biosciences Inc. is a biotechnology company that specializes in the discovery and development of novel drugs to treat various neurological and psychiatric disorders. Their research focuses on identifying and targeting specific receptors in the brain to enhance mental health and cognitive function. Bright Minds Biosciences aims to provide innovative therapeutic solutions for conditions such as depression, anxiety, schizophrenia, and Alzheimer's disease. Through a combination of cutting-edge science and advanced technologies, they are dedicated to improving the lives of individuals suffering from these disorders.


   Company Address: 19 Vestry Street NY 10013 NY
   Company Phone Number: 407-2515   Stock Exchange / Ticker: NASDAQ DRUG


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALZN        2.22% 
ATAI        7.24% 
CMND   -7.69%    
KTTA        16.95% 
SAGE        6.42% 
XENE   -2.18%    
• View Complete Report
   



Management Announcement

Bright Minds Biosciences Seeks Redemption with $35 Million Fundraising Amidst Financial Turmoil and Competitive Pressure,

Published Mon, Nov 4 2024 7:42 PM UTC

Bright Minds Biosciences: A $35 Million Gamble Amidst Dismal Financials and Industry CompetitionIn an audacious move that has raised eyebrows among investors and market analysts alike, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) has closed a non-brokered private placement, securing $35 million by selling 1,612,902 common shares at a price of $21.70 each. The ann...
Shares

Bright Minds Biosciences: A Leap into the Future with $35 Million Fueling Innovation,

Published Fri, Oct 18 2024 10:50 AM UTC

Bright Minds Biosciences Corporate Moves: A Closer Look at the $35 Million Private PlacementBright Minds Biosciences Inc., a burgeoning company in the biotechnology sector, recently made...
Clinical Study

BMB-201 A New Hope in Pain Management Amidst Financial Struggles

Published Wed, Oct 16 2024 2:46 PM UTC

In the fast-paced world of pharmaceutical innovation, Bright Minds Biosciences Inc. stands at a crucial juncture as it unveils promising data on its proprietary compound, BMB-201. This mixed agonist of the 5-HT2C and 5-HT2A receptors has shown remarkable similarities in efficacy to morphine within various preclinical pain models. This breakthrough may offer a new avenue for ...
Bright Minds Biosciences Inc

Bright Minds Biosciences Inc Shines Brightly, Delighting Shareholders with Impressive Fiscal Results



The Major Pharmaceutical Preparations sector has recently witnessed significant developments in the financial performance of Bright Minds Biosciences Inc. Although the company is yet to generate any revenue, the analysis of its fourth-quarter 2023 earnings reveals a notable improvement compared to the previous year. With a substantial reduction in the operating deficit and efforts by the executives to improve efficiency, Bright Minds Biosciences Inc is positioning itself for a prosperous future.
Positive Financial Indicators
The reported operating deficit for the period from July to September 2023 stands at $-4.521761578 million, marking a considerable decrease from $-10.381185126 million in the fourth quarter of 2022. This development demonstrates the company's efforts to control expenses and manage its financial resources more efficiently. While revenue remains at $0.00 million, the reduction in operating deficit provides hope for a brighter financial outlook for the company.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com